Dermal Filler Consent Form Template: What It Must Include

Not medical or legal advice. This page explains how filler consent forms are usually structured and what they commonly need to address. It does not set clinical standards or state the law of any state. Every consent form must be approved by your practice's medical director and reviewed by a healthcare attorney before patients sign it.

Most med spas already have a filler consent form. The trouble is that many of those forms were written for a different practice, a different product line, or a different era of aesthetic medicine, and nobody has read them line by line since they went into the intake packet. When a filler patient complains, files a board complaint, or sues, that form gets read very carefully indeed, and usually by someone looking for what it leaves out.

This guide is about one document: the consent form for dermal filler. It covers what separates the consent conversation from the signed page, who should conduct it, the elements a filler-specific form needs, how to handle hyaluronic acid and non-HA products on the same menu, how the form fits with your charting and records, and the gaps that tend to surface once a complaint arrives. The general law of consent that applies to every treatment in your practice, from the legal standard for valid consent to minors and marketing photo releases, is set out in our med spa consent forms guide, and this page does not repeat it.

We do not describe injection technique, recommend products, or give dosing, volume or timing figures here. Those belong in your clinical protocols, signed by your medical director and checked against each product's labeling. What follows is the operator's view: what the paperwork has to prove, and how to make sure it does.

Is Informed Consent the Same as a Signed Filler Consent Form?

No. Informed consent is a process: a discussion between a qualified practitioner and the patient in which the patient learns enough to make a real decision and agrees to go ahead. The signed form is the evidence that the discussion took place and what it covered. A practice can have a flawless form and still fail to obtain informed consent, and a missing signature can make a genuine conversation very hard to prove.

Operators tend to put their effort into the form because it is the visible artifact. Reviewers, insurers and plaintiffs' lawyers look past it to the process behind it. They want to know who talked to the patient, whether the patient had a chance to ask questions, whether the patient was rushed, and whether the risks discussed match the treatment actually performed. A form that was handed over at the front desk with a pen and collected thirty seconds later answers those questions badly, whatever its wording.

What the consent conversation has to cover

The discussion should walk the patient through the same territory the form records, in plain language and in a sequence that makes sense to someone who has never had filler. In practice that means:

• What the practitioner proposes to do, with which product, in which areas, and why that product suits the goal the patient described.
• What the patient can realistically expect to look like afterwards, and that results vary and fade over time.
• The alternatives, including other products, other treatments, and simply not treating.
• The common, expected reactions, so the patient does not mistake them for a complication.
• The rare but serious risks, named one by one, with the practitioner checking that the patient has understood them.
• Whether the product can be dissolved if something goes wrong or the patient dislikes the result.
• What the patient must do afterwards, which symptoms mean they should call straight away, and how to reach the practice.

The patient should have time to read the form before signing it, and an explicit invitation to ask questions. A short note in the chart recording who held the discussion, that questions were invited, and anything unusual the patient raised is worth more in a dispute than an extra paragraph of boilerplate on the form.

What the signed form actually proves

A well-built form proves four things: that this patient, on this date, was told about these specific risks for this specific product and area, and agreed to proceed. Each of those four elements can fail on its own. A form with no date cannot be tied to a visit. A form that says "dermal filler" without naming a product cannot show the patient understood what was injected. A form whose risk list is generic cannot show that the patient was warned about the event that actually happened. And a form signed after the syringe went in proves nothing about consent at all.

That is why the strongest filler forms are specific rather than long. Specific means the product, the type of filler, the treatment areas and the named serious risks are all on the page and all match the treatment record for that visit.

Who Must Obtain Consent for Dermal Filler?

The practitioner who will perform the treatment, or the practitioner who examined the patient and ordered it, should conduct the consent discussion. It should not be delegated to front-desk staff, a patient coordinator, or anyone who could not answer a clinical question about the product and its risks. Who is legally allowed to order filler, inject it and supervise it is decided state by state and by license type, so there is no single national answer to "who can sign the practitioner line."

Many med spas run on a split model, in which a physician, nurse practitioner or physician assistant performs a good-faith examination and a registered nurse or other permitted injector carries out the treatment. In that model the consent form needs to be honest about who did what. Provide separate lines for the practitioner who held the consent discussion and the practitioner who performed the injection, and make sure your delegation chart and standing orders match what the form implies. Our guide to good-faith exam requirements by state explains how that examination fits into the sequence, and the regulations by state hub sets out supervision and delegation rules for each state.

What Must a Dermal Filler Consent Form Include?

A dermal filler consent form must identify the product and whether it is hyaluronic acid or a non-HA biostimulator, the treatment areas, realistic results, alternatives, common side effects, and the serious risks, including vascular occlusion, necrosis and vision loss. It must state whether the product can be dissolved, and carry photo consent, aftercare, an emergency contact and dated signatures.

Use the list below as a checklist against your current form. Each element is then explained in turn.

1. Product and filler type — the specific product to be used, and whether it is a hyaluronic acid (HA) filler or a non-HA product such as a biostimulator.
2. Treatment areas — each area to be treated, recorded individually rather than as "face."
3. Expected results and duration — what the patient can realistically expect, described in general terms, and that results are temporary and vary between people.
4. Alternatives — other products, other treatments, and the option of not treating.
5. Common side effects — the expected, usually short-lived reactions.
6. Serious risks — vascular occlusion, tissue necrosis, rare visual impairment including blindness, nodules and granulomas, product migration, infection, and allergic reaction, each named separately.
7. Reversibility — that HA filler may be dissolved with hyaluronidase, and that non-HA products cannot be dissolved.
8. Photography consent — authorization for clinical photographs, kept separate from any marketing use.
9. Aftercare and warning signs — what to do and avoid after treatment, and the symptoms that need urgent contact.
10. Emergency contact — how to reach the practice at any hour, and when to go straight to emergency care.
11. Practitioner identity — the name and credentials of the practitioner who held the discussion and the one who will inject.
12. Signatures, date and witness — patient signature, practitioner signature, date, and a witness where your policy requires one.

Product and filler type: HA versus non-HA biostimulators

"Dermal filler" covers products that behave very differently. Hyaluronic acid fillers add volume directly and can generally be broken down by an enzyme if needed. Biostimulators, such as poly-L-lactic acid and calcium hydroxylapatite, work by prompting the body to build its own collagen over time, and no enzyme dissolves them. Permanent fillers sit in a further category. A consent form that does not say which of these the patient is receiving cannot show the patient understood one of the most important facts about their treatment.

The form should name the product to be used, not just the category, and leave space to record the product actually used if it differs on the day. Avoid a single "filler" form with every product on your menu listed and none selected; it reads as if the patient consented to all of them and understood none. If your practice offers both HA and non-HA products, either use separate forms or build a form with clearly distinct sections, each with its own risk language and its own reversibility statement. Our guide to biostimulator compliance explains why the non-HA products need a higher consent bar and their own SOPs.

Where the product's use in a particular area is outside its labeled indications, say so on the form. Patients are entitled to know when a treatment is being used off-label, and a reviewer will expect the form to reflect the product labeling rather than the marketing around it.

Treatment areas and the treatment plan

List each area separately: cheeks, temples, jawline, chin, under-eye hollows, nasolabial folds, lips, and so on, as your menu requires. "Face" or "as discussed" is not a treatment area. Some areas carry a higher risk of serious vascular events than others, and the form is the right place to flag that the patient is being treated in one of them. Our filler complications guide explains which central-face areas are generally regarded as higher risk and why.

Record the areas the patient consented to before treatment. If the practitioner and the patient agree on an additional area during the appointment, update the form and have both parties initial the change before the extra area is treated. A treatment record that shows more areas than the consent form is one of the easiest gaps for a reviewer to spot.

Expected results and duration, in general terms

The form should describe what the patient can reasonably expect: that filler adds volume or changes contour in the treated area, that the final appearance is not visible immediately because of swelling, that results vary from person to person, and that the effect is not permanent for HA products and gradual for biostimulators. Keep duration language general. A specific number of months printed on a form becomes a promise, and the patient whose result fades sooner will hold it against you.

State plainly that more than one session or a later adjustment may be needed, and that the practice cannot guarantee a particular cosmetic outcome. If your practice has a touch-up or correction policy, say what it is, or refer to a separate written policy the patient has received. Expectation-setting is not a legal nicety: a large share of filler disputes are about the result rather than a medical complication, and the form is where the expectation was set.

Alternatives

Informed consent requires that the patient knew there were other options. For filler, those usually include a different filler product, a different treatment altogether such as a neuromodulator, energy-based device or biostimulator series, a surgical option where relevant, and the option of not treating at all. The form does not need to argue the merits of each one. It needs to record that alternatives were discussed and that the patient chose this treatment knowing they existed.

Common side effects

List the expected reactions so the patient recognizes them as normal: swelling, bruising, redness, tenderness, temporary lumpiness or unevenness, and mild discomfort at the injection sites. Explain that these usually settle on their own, without putting a fixed timeline on the form. Patients who were never told to expect swelling and bruising tend to treat them as evidence of a mistake, and an unhappy patient who believes they have been injured is the patient most likely to complain.

Keep common reactions visibly separate from serious risks on the page. When bruising and blindness sit in the same sentence, the patient tends to read the whole list as routine, and a reviewer may conclude the serious risks were never singled out for discussion.

Serious risks the form must name

This is the section that does the most work in a dispute, and the one most often written too vaguely. Each serious risk should appear on its own line, in plain language, with a brief description of what it means for the patient. Your form should name at least:

• Vascular occlusion. Filler can enter or compress a blood vessel and interrupt blood flow to the tissue it supplies. This is an emergency that the practice will treat under its own protocol.
• Tissue necrosis. If blood flow is not restored, the affected skin can be damaged or die, which may lead to wounds and permanent scarring.
• Visual impairment, including blindness. Rarely, filler that enters a blood vessel can reach the vessels supplying the eye and cause vision loss, which may be permanent. This must be stated directly, not implied by a phrase like "vascular complications."
• Nodules and granulomas. Lumps can form soon after treatment or appear much later, including inflammatory reactions that may be triggered by an illness or another event. Some need treatment; some persist.
• Migration. Product can move or spread beyond the area where it was placed, changing the appearance of the treated area or the surrounding tissue.
• Infection. Any injection can introduce infection, including low-grade infections that appear later.
• Allergic or hypersensitivity reaction. Reactions to the product or its components can occur, from local swelling to, rarely, a severe allergic reaction requiring emergency care.

Depending on your products and areas, your medical director may add others, such as a bluish discoloration from superficial placement, reactivation of cold sores in perioral treatment, or asymmetry requiring correction. The product labeling is the starting point for what each product's form must disclose.

Do not dress the serious risks in reassurance. Phrases like "extremely rare" or "almost never happens" weaken the disclosure, and you have no reliable figure to back them with. The safer formulation is the plain one: the risk is rare, it is serious, and it can happen even when treatment is performed correctly. The ways these events are recognized and managed belong in your clinical protocols, covered in depth in our vascular occlusion protocol guide; the form's job is to show the patient was told they can happen.

Dissolving: what hyaluronidase can and cannot do

Patients often hear that filler "can always be dissolved." That is true only for hyaluronic acid products, and even then dissolving may not be complete or perfectly even. The consent form should say, in one or two plain sentences, that HA filler may be dissolved with an enzyme called hyaluronidase if there is a complication or the patient wants it removed, and that biostimulators and permanent fillers cannot be dissolved this way.

For an HA product, it helps to add that hyaluronidase is itself a medication with its own risks, including allergic reaction, and that any elective dissolving would be discussed and consented to separately. For a non-HA product, the statement that the treatment cannot be reversed should be prominent, because it changes the decision the patient is making. Our hyaluronidase and dissolving filler guide covers the separate dissolving consent and the readiness requirements around the drug itself.

Photography consent

Standardized before-and-after photographs are a clinical baseline and, in a dispute about the result, often the most persuasive evidence available. The filler form should include consent to take clinical photographs for the medical record. Using those images in marketing, on social media, or in training materials is a different decision with different rules, and it needs its own separate, revocable authorization rather than a checkbox at the bottom of the treatment consent. Our before-and-after photo rules guide covers the advertising side.

Aftercare instructions and warning signs

The form should confirm that the patient received written aftercare instructions and understood them. The instructions themselves can live on a separate handout, which is easier to keep up to date, but the form should record that the handout was given and reviewed. Our aftercare instructions template guide covers what those handouts should contain.

The warning signs need to be on the consent form itself, not only on the handout, because they are part of the risk disclosure. The patient should be told to contact the practice immediately for pain that is severe or worsening, skin that turns pale, white, dusky or blotchy, a spreading or net-like discoloration, a treated area that feels cold, blistering, signs of infection such as spreading redness or fever, or difficulty breathing or facial swelling suggestive of an allergic reaction. Any change in vision, severe headache, or weakness should be treated as an emergency.

Emergency contact

Give the patient a number that is answered outside business hours, or a clear instruction on what to do when the practice is closed. A daytime front-desk line with a voicemail box is not an emergency contact. The form should also state that, for vision changes, breathing difficulty or other severe symptoms, the patient should call emergency services or go to the nearest emergency department rather than wait for a call back, and that the practice may transfer the patient to emergency care if a serious complication occurs during treatment.

Practitioner identity, signatures, date and witness

Print the name and credentials of the practitioner who held the consent discussion and, where different, the one who will perform the injection. A signature line with an illegible scrawl and no printed name is of little use when someone needs to establish who was responsible. The patient signs and dates the form before treatment; the practitioner signs to confirm they conducted the discussion and answered the patient's questions. Whether a third-party witness is required is a matter for your state's rules and your counsel; if your policy calls for one, the witness should be someone who actually observed the signing.

Include an attestation in the patient's own words, or at least in first person: that they read the form, had the chance to ask questions, had their questions answered, and agree to proceed. Many practices also have the patient initial beside each serious risk. Initials do not replace the conversation, but they make it hard to argue later that a particular risk was never pointed out.

Does Lip Filler Need Its Own Consent Form?

Lip filler uses the same core consent elements as any other HA filler, but the lips bring their own expectation, swelling and migration issues that the form needs to address. Many practices therefore use a lip-specific form or a lip section within the filler form. Our lip filler safety and consent guide covers what that form should add and how to manage the expectation conversation.

How Much Should the Form Say About Vascular Events?

Enough for the patient to understand the risk, and no more. The form should name vascular occlusion, tissue necrosis and vision loss, explain each in a sentence the patient can follow, say that the practice has an emergency protocol, and say that the patient may need to be transferred to emergency care. It should not attempt to describe the clinical response, list medications or doses, or promise any particular outcome from treatment. A form that tries to teach the occlusion protocol becomes harder to read, goes out of date as the protocol changes, and invites argument about whether the practice did what the form described.

The clinical side of these events, from recognition to escalation, belongs in your written protocols and is covered in our vascular occlusion guide and our hyaluronidase protocol guide. The consent form should be consistent with those protocols: if the form says the practice keeps hyaluronidase on site and has an occlusion protocol, both had better be true on the day of treatment.

How Should You Document and Store Filler Consent?

The consent form is one part of the filler record, and it is only as strong as its connection to the rest. A signed form that cannot be matched to a specific treatment, product and lot is far weaker than a modest form that sits inside a complete, consistent chart.

Linking the form to the treatment record

The chart for each filler visit should show, at a minimum, the consent form for that visit, the good-faith examination or assessment, the product actually used with its lot number, the areas treated, pre-treatment photographs, and confirmation that aftercare instructions were given. The product and areas on the consent should match the product and areas in the treatment note. Where they differ, the chart should show why and that the patient agreed to the change before it happened. Recording the lot number matters for traceability if a product problem emerges later and for any report to the manufacturer.

Health history belongs in the chart too. The consent discussion relies on knowing the patient's allergies, medications, previous filler and its type, and conditions that affect risk. Our intake form template guide covers what to collect and how to keep it current.

How long to keep signed filler consent forms

Signed consent forms are part of the medical record and follow the same retention rules as the rest of the chart. Those rules come from state law and other requirements that vary, so there is nothing filler-specific to add here. Our medical records retention guide covers how long to keep records and how to store them.

Keep superseded versions of the form template as well as the signed copies. If a patient treated two years ago complains, the question is what the form said then, not what it says now. A simple version log, recording the date each version went into use, who approved it, and what changed, answers that question in minutes.

Electronic signatures

Many practices now collect filler consent on a tablet or through a patient portal. Electronic signature is widely used for consent documents, but the platform has to be able to show who signed, exactly which version of the form they saw, and when they signed it. A system that captures a signature image but cannot reproduce the text the patient agreed to is a weak record. Before relying on e-consent, confirm with counsel that your platform and process meet the requirements that apply in your state, and make sure signed forms are stored securely with the rest of the record.

Watch for two problems that are specific to electronic forms. The first is the scroll-past: if the patient can reach the signature box without the risk section ever being displayed, the record proves less than it appears to. The second is silent template drift: when someone edits the form in the platform, older signed forms may end up displaying the new text. Version locking, so that each signed form preserves the exact text the patient saw, avoids that.

When do you need a new filler consent?

Re-consent whenever something material changes. For filler, the common triggers are:

• A new product, especially a move from an HA filler to a biostimulator or the reverse, because the reversibility statement and the risk profile change.
• A new treatment area, particularly one your medical director regards as higher risk.
• A change in the patient's health: new medications, a new diagnosis, pregnancy, a recent illness or infection, or a reaction to a previous treatment.
• A complication at a previous visit, which should prompt a fresh discussion before any further treatment.
• A new version of your consent form, so that returning patients sign the current wording.
• A different practitioner conducting the discussion or performing the treatment, where that changes who the patient is consenting to.

Many practices simply obtain a new signed consent at every filler visit, which removes the need to judge whether a change is material. Whatever policy you adopt, write it down and follow it consistently; a policy applied to some patients and not others is harder to defend than either approach applied uniformly.

What Should a Dermal Filler Consent Form Template Look Like?

A usable template is organized so that a patient can read it in order and a reviewer can find each required element quickly. The outline below is a common structure. It is a layout, not wording to copy; your medical director and counsel should supply the final text.

Is There a Free Dermal Filler Consent Form PDF You Can Use?

A free filler consent PDF can be a starting point, but it is not ready to use. It has to match the products you actually inject, be approved by your medical director, and fit the law of your state before any patient signs it. A generic download cannot know whether you use HA fillers, biostimulators or both, which areas you treat, how your emergency pathway works, or what your state requires of consent and delegation.

When you evaluate a free or purchased template, check it against the element list above. Look in particular for a product field rather than a generic "filler" label, a reversibility statement that distinguishes HA from non-HA products, serious risks named individually including vision loss, warning signs and an emergency contact, and separate practitioner and patient signature lines. Then adapt it: replace every generic term with your own products and areas, align the risk language with your clinical protocols, and add your version number and approval date.

Do not copy a manufacturer's patient materials into your form or present them as your consent. Use each product's labeling as a source for what must be disclosed, and write your form in your practice's own words, approved by your own medical director.

What Filler Consent Form Mistakes Show Up in Complaints?

When a filler complaint reaches a board, an insurer or a court, the consent form is usually one of the first documents requested. The same handful of weaknesses appear again and again.

One generic form for every injectable

A single "injectables consent" that covers neuromodulators, fillers and everything else tends to describe none of them well. The serious filler risks get diluted among toxin risks, and the reversibility question is not addressed at all. Filler deserves its own form, and so do the products within it that behave differently.

The product is never named

If the form says "dermal filler" and the chart says a specific product, the patient can argue they never knew what was being injected. Name the product on the form and make sure it matches the treatment note.

HA and non-HA products are treated as interchangeable

The most damaging version of this mistake is a form, or a staff script, that tells a biostimulator patient the result "can be dissolved." That statement is wrong for non-HA products, and a patient who relied on it has a strong argument that they were misinformed. Make the reversibility statement product-specific, and train staff never to offer reassurance the form does not support.

The catastrophic risks are buried or softened

Vision loss mentioned only as part of "vascular complications," or necrosis listed after bruising in small print, is a disclosure in name only. If the event that happened is not clearly on the form, the defense that the patient was warned becomes much harder.

The form was signed at the wrong time

Forms signed after treatment, signed in a hurry at check-in before the patient has met the practitioner, or left unsigned and completed later all undermine the record. Consent has to precede treatment and follow the discussion.

An area was added without updating the consent

"While you're here, shall we do the chin as well?" is a common conversation and a common gap. If the extra area is not on the consent, the treatment of that area is effectively undocumented.

The wrong person obtained consent

A form explained by a coordinator who could not answer clinical questions, or signed on the practitioner line by someone who never spoke to the patient, invites the argument that informed consent was never obtained at all.

No warning signs or emergency contact

When a patient with a developing complication waited overnight because they did not recognize the symptoms or could not reach anyone, the absence of warning signs and an after-hours contact on the form becomes part of the complaint.

The form no longer matches the practice

New products, new areas and new staff arrive; the form stays the same. A form that refers to products you no longer use, or omits ones you now inject, tells a reviewer that nobody is maintaining it.

How Do the Consent Form and Your Filler SOPs Fit Together?

The consent form is a summary for the patient of risks your protocols manage for the practice. The two need to agree. If your SOPs treat delayed nodules, migration and allergic reactions as known events with defined responses, the form should name them. If your occlusion protocol depends on hyaluronidase and an escalation pathway, the form should tell the patient that the practice has an emergency protocol and may transfer them to emergency care. If your SOP requires a good-faith examination before every new product or area, the consent workflow should make it impossible to sign before that exam is recorded.

A useful exercise is to lay your filler SOP next to your consent form and check each risk the SOP addresses against the form, and each statement the form makes against what the practice actually does. Any mismatch is a liability: a risk the SOP anticipates but the form never mentions, or a reassurance the form gives that the protocol does not support. Our injectables safety and compliance guide maps the wider program the consent form belongs to.

How Does Filler Consent Differ From Neurotoxin Consent?

The two forms share a structure, but the risks they need to emphasize are different. Neurotoxin consent centers on effects spreading beyond the injection site, temporary drooping, and a result that wears off. Filler consent centers on a physical product in vascular tissue, risks that can be permanent, and the question of whether the product can be removed. Using one form for both, or adapting a toxin form for filler by changing the title, usually leaves the filler-specific risks underdeveloped. Our guide to Botox consent forms covers the neurotoxin form element by element, and our microneedling consent form template guide applies the same structure to microneedling, RF microneedling and PRP.

Key Takeaways

• Informed consent is the discussion; the signed form is the proof. Both are needed, and the form cannot replace the conversation.
• The consent discussion should be held by a practitioner qualified to answer clinical questions, and the form should identify who held it and who injected.
• Name the product and say whether it is hyaluronic acid or a non-HA product. The reversibility statement depends on it.
• List each treatment area, and update the form before treating an area that was not on it.
• Name the serious risks individually: vascular occlusion, tissue necrosis, visual impairment including blindness, nodules and granulomas, migration, infection and allergic reaction.
• Keep clinical photography consent and marketing authorization separate.
• Put the warning signs and an after-hours emergency contact on the form itself.
• Tie each signed form to the treatment record, product and lot, and keep version history.
• Re-consent when the product, area, practitioner or the patient's health changes, or adopt per-visit consent.
• A template is a starting point; your medical director approves it and counsel reviews it.

This guide is general information about how dermal filler consent forms are structured and maintained. It is not medical or legal advice, does not set clinical standards and does not state the law of any state. Every consent form must be approved by your practice's medical director and reviewed by a healthcare attorney licensed in your state before use, and the risk disclosures for each product should be checked against its current labeling.